Simon Wöhrle

Title: Simon Wöhrle: Innovator in Pharmaceutical Research

Introduction

Simon Wöhrle is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of hypophosphatemic disorders. His innovative work has led to the development of a unique FGFR inhibitor, which holds promise for various medical conditions.

Latest Patents

Simon Wöhrle holds 1 patent for his invention titled "FGFR inhibitor for use in the treatment of hypophosphatemic disorders." This patent relates to the compound 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or its pharmaceutically acceptable salts or solvates. The invention is aimed at treating conditions such as X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), and several other related disorders.

Career Highlights

Simon Wöhrle is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on groundbreaking research and development in the pharmaceutical sector. His contributions have been instrumental in advancing treatment options for patients suffering from hypophosphatemic disorders.

Collaborations

Throughout his career, Simon has collaborated with esteemed colleagues, including Michaela Kneissel and Vito Guagnano. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Simon Wöhrle's contributions to pharmaceutical research exemplify the impact of innovation in medicine. His work continues to pave the way for new treatments that can improve the quality of life for many patients.